Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy

[1]  H. Hashimoto,et al.  A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy , 2018, International Journal of Clinical Oncology.

[2]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[3]  Eun Jeong Kim,et al.  NCCN Guidelines Insights: Antiemesis, Version 2.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  U. Permsuwan,et al.  Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. , 2017, Critical reviews in oncology/hematology.

[5]  Legese Chelkeba,et al.  Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis , 2017, Pharmacy practice.

[6]  W. Encinosa,et al.  Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations , 2017, JAMA oncology.

[7]  E. Bruera,et al.  2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. Loprinzi,et al.  Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. , 2016, The New England journal of medicine.

[9]  M. Aapro,et al.  Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. , 2016, The New England journal of medicine.

[10]  Rosanna Tarricone,et al.  Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review. , 2016, Critical reviews in oncology/hematology.

[11]  A. Clemmons,et al.  Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy‐Induced Nausea and Vomiting , 2016, Pharmacotherapy.

[12]  R. Chow,et al.  Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis , 2016, Supportive Care in Cancer.

[13]  F. Roila,et al.  A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. , 2015, Critical reviews in oncology/hematology.

[14]  G. Dranitsaris,et al.  Defining optimal control of chemotherapy-induced nausea and vomiting—based on patients’ experience , 2015, Supportive Care in Cancer.

[15]  H. Zhang,et al.  QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. , 2015, European journal of cancer care.

[16]  Emily R. Hajjar,et al.  Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Hirashima,et al.  Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial , 2014, Supportive Care in Cancer.

[18]  N. Masumori,et al.  Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. , 2014, Journal of pain and symptom management.

[19]  G. Kichenadasse,et al.  Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review , 2014, Supportive Care in Cancer.

[20]  Stephen T. Sonis,et al.  The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue , 2013, PharmacoEconomics.

[21]  R. Navari,et al.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy , 2013, Supportive Care in Cancer.

[22]  G. Nocea,et al.  Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life , 2012, Supportive Care in Cancer.

[23]  R. Navari,et al.  Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. , 2011, The journal of supportive oncology.

[24]  F. Greenway,et al.  Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men , 2010, Obesity.

[25]  Xiuli Liu,et al.  Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting , 2009, Journal of experimental & clinical cancer research : CR.

[26]  Panagiotis Mavros,et al.  Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Morrow,et al.  Patient expectation is a strong predictor of severe nausea after chemotherapy , 2004, Cancer.

[28]  Sin-Ho Jung,et al.  A Phase I Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients: A Hoosier Oncology Group Study , 2004, Cancer investigation.

[29]  R. de Wit,et al.  Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Passik,et al.  A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. , 2003, Journal of pain and symptom management.

[31]  D. Allison,et al.  Antipsychotic-induced weight gain: a review of the literature. , 2001, The Journal of clinical psychiatry.

[32]  Philip Seeman,et al.  Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.

[33]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Stephen Szabo,et al.  Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. , 2014, Journal of oncology practice.

[35]  W. Pirl,et al.  Remission of chemotherapy‐induced emesis with concurrent olanzapine treatment: a case report , 2000, Psycho-oncology.